Highlights From ILCS24

The 6th International Lung Cancer Summit was held in Lausanne, Switzerland on October 4, 2024, by HUG, CHUV, OncoViews and PEAK Medicals.

The ILCS24 provided insights into the latest breakthroughs and developments in lung cancer treatment, featuring leading global experts discussing advances in thoracic oncology. Distinguished speakers from the USA, Spain, UK, Italy, Netherlands, France, Austria, and Switzerland participated in the event.

This conference utilized digital platforms to promote meaningful engagement and networking opportunities for attendees from medical offices, universities, and institutes, enabling them to connect with esteemed medical oncologists and industry professionals at the forefront of lung cancer treatment and research.

The 6th International Lung Cancer Summit was hosted by Solange Peters and Alfredo Addeo.

Here are some highlights from the event:

Alfredo Addeo:

“After 1 long year, the ILCS24 is about to start. Join us tomorrow. Honored to co-chair it with Solange Peters and to share the stage with such great faculty Stephen Liu, Jarushka Naidoo, Sandip Patel, Roberto Ferrara, Biagio Ricciuti, Dr. Schultheis, Dr. Dingemans, Giannis Mountzios, Jordi Remon, Dr. Novoa, HUG, CHUV.”

Stephen Liu:

“ILCS24. Dr. Biagio Ricciuti helps demystify KRAS NSCLC. Important first-gen drugs for KRAS G12C include sotorasib and adagrasib with new drugs in development including agents targeting other mutations such as KRAS G12D – more common overall in oncology.”

Katsuaki Maehara:

“ILCS24

This year’s summit was again full of lively discussions and highly significant.

I would like to thank all the faculty and all the participants.

And most of all, thank you to Solange Peters and Alfredo Addeo for chairing the summit.”

Timothée Olivier:

“Great to be attending in person to the 6th ILCS24 hosted by Solange Peters and Alfredo Addeo and great panelists!
Let’s get started! (+ attend online!)”

Biagio Ricciuti:

“Great overview of the treatment landscape for RET, MET, and NTRK positive NSCLC by Roberto Ferrara. On target and off target resistance rates differ across these driver alterations.”

Giannis Mountzios:

“ILCS24. Insightful critical overview by Anne-Marie Dingemans on novel approaches for EGFR and ALK-positive disease.”

Jordi Remon:

“In early-stage NSCLC IO is a reality with several approvals by FDA/EMA. ADJ trials with IO ‘more controversial’, Hwv, neoadjuvant and perioperative CT+O trials more consistent results. Are we sure perioperative IO is better than only induction CT+IO in OS? Overtreating lungs with pCR?”

Sandip Patel:

“Phenomenal talk by Stephen Liu on IO strategies in SCLC from LS-SCLC to 1L ES-SCLC with chemo+anti-PD-L1 and DLL3 BiTE in 2L. Steady improvement in a difficult disease.”

Roberto Ferrara:

“Very ‘out of box’ overview of ICI treatment duration in NSCLC from Giannis Mountzios at ILCS24.

2 years versus 5 years ICI: 186.000.000 euros spared: the cost to build a cancer hospital.”

Stephen Liu:

“Dr. Sandip Patel at ILCS24 debating the stance of indefinite immunotherapy. Notes that 2 years of therapy is arbirtrary and in the event of relapse after stopping therapy, only 1/3 will respond again. Better approach is biomarker driven duration i.e. MRD.”

Giannis Mountzios:

“With ILCS24 coming to an end, we all head back a bit wiser, happily overwhelmed with new therapeutic options, and grateful to our hosts Alfredo Addeo and Solange Peters and this amazing global oncology family!! Safe travels et à la prochaine!!”

Aadil Najeed:

“Just attended the International Lung Cancer Summit 2024, and I can confidently say it was the finest conference I’ve ever been part of! The level of expertise, groundbreaking research, and collaboration was truly inspiring. From innovative treatment approaches to life-saving technologies, this summit showcased the very best in the fight against lung cancer.”

Marc Terrones:

“Glad to be in Lausanne for the ILCS24. The recent advances in ADCs are definitely promising and the way to go!

Among the speakers, there’s a common request: the need for further translational research to understand the intricate tumor biology that modulates treatment response. Together we unite efforts to answer these questions.”

More posts featuring ILCS24.